Investments, Funding & Disinvestment

Idefirix is a first-in-class treatment designed to help highly sensitised adult kidney transplant patients who face difficulties finding compatible donors.

The acquisition reflects a long-term strategic collaboration between the two companies, with Artivion already serving as the exclusive distributor of NEXUS across Europe, the Middle East, and Africa since 2019.

Owen Mumford brings established expertise in device design, precision moulding, and medical device assembly, which will now be integrated with Embecta’s commercial infrastructure and large-scale manufacturing capabilities.

The funding comes as health authorities across the continent intensify efforts to contain the rapidly evolving outbreak linked to the Bundibugyo strain of the Ebola virus.

Under the licensing arrangement, the Medicines Patent Pool (MPP) has invited qualified generic drug manufacturers to submit applications to produce generic versions of Xofluza.

Under the collaboration, the companies will evaluate Helicons both as standalone therapies and as payloads linked to Regeneron antibodies.

This agreement also grants Boston Scientific an exclusive option to acquire the TAVR programme, subject to additional payments and to clinical and regulatory milestones.

The facility is built to accommodate approximately 1,000 to 1,500 healthcare professionals each year, including consultants, specialists, and early-career doctors.

The JV combines Arna Pharma’s formulation development expertise and portfolio expansion strategy with Slate Run Pharmaceuticals’ established US commercial operations, regulatory capabilities, and supply chain infrastructure.

Cellular Intelligence plans to continue the clinical development of the Parkinson’s therapy using its proprietary artificial intelligence platform, which is designed to optimize cell therapy manufacturing and accelerate development timelines.